|
EDITION
CONTENT TYPE
Act
Admin Code
Announcements
Bill
Book
CADD File
CAN
CEU
Charter
Checklist
City Code
Code
Commentary
Comprehensive Plan
Conference Paper
County Code
Course
DHS Documents
Document
Errata
Executive Regulation
Federal Guideline
Firm Content
Guideline
Handbook
Interpretation
Journal
Land Use and Development
Law
Legislative Rule
Local Amendment
Local Code
Local Document
Local Regulation
Local Standards
Manual
Model Code
Model Standard
Notice
Ordinance
Other
Paperback
PASS
Periodicals
PIN
Plan
Policy
Product
Product - Data Sheet
Program
Provisions
Requirements
Revisions
Rules & Regulations
Standards
State Amendment
State Code
State Manual
State Plan
State Standards
Statute
Study Guide
Supplement
Sustainability
Technical Bulletin
All
|
Content DescriptionThis document provides guidance for assessment and evaluation of planned changes to drug delivery systems that are integral with, packaged with, or cross-labelled for use with a specified medicinal product. This document is applicable to the drug delivery system's lifecycle from registration clinical studies to end-of-life. This document is applicable to the assessment of changes within the following drug delivery systems: — needle-based injection systems for medical use; — aerosol drug delivery devices; — needle-free injectors for medical use. NOTE These are covered by the ISO 11608 series, ISO 20072 and ISO 21649, respectively. This document might also be useful for assessing and evaluate changes to other drug delivery devices or systems. Examples of changes that are within the scope of this document include but are not limited to the following: a) the same route of administration (e.g. change resulting in including a marketed prefilled syringe to an autoinjector); b) changes to the drug delivery system design (e.g. change in configuration or layout of electrical and mechanical components); c) changes to the medicinal product that affect the drug delivery system; including the primary container closure (e.g. viscosity, particle size); d) changes in production or handling of the drug delivery system (e.g. process scale, manual to automated assembly, glue bond to sonic weld, mould cavitation, sterilization, storage, transportation, work instructions or methods); e) changes in component materials or source of supply; f) changes in software, including changes related to cybersecurity, encryption and connectivity; g) changes in the user interface, including packaging; h) changes to labelling and/or instructions for use. Revisions or additions of software are within the scope of this document. The software can either be integrated into the physical drug delivery system, separate, or both. The applicability of this document to non-integrated software is relevant to the extent that those software changes can impact the drug delivery system and/or impact how users interact with it. Depending on the nature of the change, there can be additional assessments and resulting activities, which can be outside the scope of this document. This document does not provide guidance for defining the objective of the change, nor the various potential opportunities/options for fulfilling this objective. The following editions for this book are also available...
About ISOISO, the International Organization for Standardization, brings global experts together to agree on the best way of doing things – for anything from making a product to managing a process. As one of the oldest non-governmental international organizations, ISO has enabled trade and cooperation between people and companies all over the world since 1946. The International Standards published by ISO serve to make lives easier, safer and better. |
GROUPS
|